Compassionate Use of Intravitreal Pegaptanib in Patients with Age-Related Macular Degeneration

REFERENCES

• Otani A, Takagi H, Oh H et al. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res 2002; 64:162–169.
   PubMed Web of Science ®Google Scholar
• Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997; 81:154–162.
   PubMed Web of Science ®Google Scholar
• Kvanta A, Algvere PV, Berglin L, Seregrad S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996; 37:1929–1934.
   PubMed Web of Science ®Google Scholar
• Eyetech Study Group. Preclinical and phase 1. A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002; 22:43–152.
   Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351:2805–2816.
   PubMed Web of Science ®Google Scholar
• Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 2005; 25:119–134.
   Google Scholar
• World Health Organization. International Classification of Diseases and Related Health Problems, 10th Revision. Geneva, Switzerland: World Health Organization, 1992; 456–457.
   Google Scholar
• D’Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, Guyer DR, Katz B. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006; 113:992–1001.
   PubMed Web of Science ®Google Scholar
• Singerman LJ, Masonson H. Patel M, Adamis AP, Buggage R, Cunningham E, Goldbaum M, Katz B, Guyer D. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 2008; 92 (12): 1606–1611.
   Google Scholar
• Gonzales CR, VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina 2005; 25:815–827.
   PubMed Web of Science ®Google Scholar
• Quiram PA, Hassan TS, Williams GA. Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib. Retina 2007; 27:851–856.
   Google Scholar
• Ehlers JP, Fintak DR, Gupta OP, Regillo CD, Fineman MS, Ho AC. Pegaptanib for choroidal neovascularization in treatment-naïve exudative age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2007; 38:371–377.
   Google Scholar
• Tano Y, Pegaptanib Sodium Multi-center Study Group. Pegaptanib sodium one-year treatment study for neovascular age-related macular degeneration. Nippon Ganka Gakkai Zasshi 2008; 112:590–600.
   Google Scholar
• Atmani K, Coscas F, Coscas G, Soubrane G. Pegaptanib sodium for occult choroidal neovascularization in neovascular age-related macular degeneration: a prospective case series. Eye 2009; 23:1150–1154.
   Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1419–1431.
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S. ANCHOR study group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1432–1444.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ. Intravitreal avastin: the low cost alternative to lucentis? Am J Ophthalmol 2006; 142:141–143.
   PubMed Web of Science ®Google Scholar
• Schouten JS, La Heij EC, Webers CA, Lundqvist IJ, Hendrikse F. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2009; 247:1–11.
   PubMed Web of Science ®Google Scholar
• Patel PJ, Bunce C, Tufail A, Abc Trial Investigators OB. A randomised, double-masked phase III/IV study of the efficacy and safety of Avastin(R) (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration: Clinical trial design. Trials. 2008; 14;9:56.
   Google Scholar
• Farah SE. Treatment of neovascular age-related macular degeneration with pegaptanib and boosting with bevacizumab or ranibizumab as needed. Ophthalmic Surg Lasers Imaging 2008; 39:294–298.
   Google Scholar